The National Lung Matrix Trial (NLMT) is the first UK trial to combine the development of a technology platform that screens for multiple genetic aberrations in tumours (provided by CRUK’s SMP2) with testing of multiple novel genetic-marker-directed drugs. The trial is focused on patients with advanced NSCLC and currently includes 8 drugs: 7 targeted treatments for patients with one of 20 molecular markers, and additionally a monoclonal antibody for the treatment of patients with no actionable mutations
The ECMC Programme Office work closely with the press team at Cancer Research UK (CRUK) to maximise the impact of the research that the Network supports.
Help us to identify ECMC-supported research by letting us know when you submit a paper or other outputs of your research. This ensures that the press team have the maximum amount of time to work with us to produce relevant press content.
Velindre Cancer Centre’s Clinical Trials Unit (CTU), which is part funded by the Cardiff ECMC, was recently shortlisted for an NHS Wales award.
The awards are an opportunity to showcase local health efforts and ensure improvement stays at the forefront of the NHS. The unit was selected as one of the three shortlisted candidates in the ‘Promoting Clinical Research and Application to Practice’ category for their efforts in giving patients access to new Phase I drugs.
A new study led by researchers at Glasgow ECMC will treat pancreatic cancer patients whose cancer has grown too big to be removed by surgery but has not yet spread to other parts of the body.
The team will give patients on the trial a drug called olaparib, in addition to the standard treatment of chemotherapy and radiation known as chemoradiation. The hope is that the combination will make the tumour small enough to be removed by surgery in these patients.
Researchers at Glasgow ECMC – in collaboration with the CRUK Clinical Trials Unit and Beatson West of Scotland Cancer Centre in Glasgow - are part of a UK-wide team that aim to evaluate the use of saracatinib (also known as AZD0530) as a new combination therapy for the treatment of advanced prostate cancer.
Sheffield ECMC is pleased to announce the opening of the CARBON study, which is a randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases. This academic study is funded by Bayer, and led by Professor Rob Coleman and Professor Janet Brown of the Sheffield ECMC. It is the first study to assess radium-223 with chemotherapy in advanced breast cancer.
We are pleased to announce that the ECMC Secretariat has undergone a name change and will now be referred to as the ECMC Programme Office. This is to reflect the added functionality that the Programme Office will have moving forward, including more proactive engagement with industry to enhance delivery and performance across the ECMC Network.
In addition, the ECMC Combinations Alliance team – Lyndall, Cathy, Julie, Zoe and Amy – have joined forces to sit within the newly-formed ECMC Programme Office team.